ACIU AC Immune SA

4.35
-0.28  -6%
Previous Close 4.63
Open 4.66
Price To Book 1.54
Market Cap 293027702
Shares 67,362,690
Volume 673,570
Short Ratio
Av. Daily Volume 630,147

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 commencement of dosing announced November 2, 2017.
RO7105705
Alzheimer’s disease
Phase 1/2 interim data due 1Q 2019 est.
ACI-24 (anti-Abeta vaccine)
Alzheimer's disease-like characteristics in individuals with Down syndrome
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 2 trial initiation announced August 20, 2018.
ACI-24
Alzheimer’s disease
Phase 2 trial initiation announced February 20, 2019.
MTAU9937A
Alzheimer’s disease

Latest News

  1. Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
  2. Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
  3. What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
  4. AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease
  5. AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
  6. What Makes AC Immune (ACIU) a New Buy Stock
  7. AC Immune Enters Oversold Territory
  8. Why AC Immune SA Stock Crashed on January 30
  9. Roche Halts Two Late-Stage Studies on Alzheimer's Candidate
  10. Roche Scraps Alzheimer's Test — But Investors Punished This Stock
  11. Roche, AC Immune drop Alzheimer drug trials after setback
  12. Why AC Immune SA Is Imploding
  13. Genentech kills big drug study in early Alzheimer's patients
  14. Roche drops Alzheimer drug trials after setback
  15. AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease
  16. Top Ranked Momentum Stocks to Buy for January 25th
  17. Moving Average Crossover Alert: AC Immune
  18. Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher
  19. Biogen Inks Two Deals to Make Drugs for Neurological Diseases
  20. AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer